Comparison of plasma and urinary microRNA-483-5p for the diagnosis of adrenocortical malignancy

Decmann, Ábel; Bancos, Irina; Khanna, Aakanksha; Thomas, Melinda; Turai, Péter István; Perge, Pál; Pintér, J; Tóth, Miklós; Patócs, Attila; Igaz, Péter

doi:10.1016/j.jbiotec.2019.03.017

Cited by 17 publications

(23 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In dogs with csACTs, miR-483-3p was significantly overexpressed compared to healthy dogs. In humans, miR-483-5p, the reverse miRNA from the miR-483 locus, is one of the most commonly reported circulating miRNA that is overexpressed in patients with ACC compared to those with ACA (49)(50)(51). Although miR-483-3p is less studied, it is also overexpressed in ACC compared to ACA in humans (45).…”

Section: Discussionmentioning

confidence: 99%

Circulating microRNAs as noninvasive biomarkers for canine Cushing’s syndrome

Sanders

Veldhuizen

Kooistra

et al. 2021

Preprint

View full text Add to dashboard Cite

Canine Cushing′s syndrome (hypercortisolism) can be caused by a pituitary tumor (pituitary-dependent hypercortisolism; PDH) or a cortisol-secreting adrenocortical tumor (csACT). For both cases, noninvasive biomarkers that could pre-operatively predict the risk of recurrence after surgery would greatly impact clinical decision making. The aim of this study was to determine whether circulating microRNAs (miRNAs) can be used as noninvasive biomarkers for canine Cushing′s syndrome. After a pilot study with 40 miRNAs in blood samples of healthy dogs (n = 3), dogs with PDH (n = 3) and dogs with a csACT (n = 4), we selected a total of 20 miRNAs for the definitive study. In the definitive study, these 20 miRNAs were analyzed in blood samples of healthy dogs (n = 6), dogs with PDH (n = 19, pre- and post-operative samples) and dogs with a csACT (n = 26, pre-operative samples). In dogs with PDH, six miRNAs (miR-122-5p, miR-126-5p, miR-141-3p, miR-222-3p, miR-375-3p and miR-483-3p) were differentially expressed compared to healthy dogs. Of one miRNA, miR-122-5p, the expression levels did not overlap between healthy dogs and dogs with PDH (p = 2.9x10-4), significantly decreased after hypophysectomy (p = 0.013), and were significantly higher (p = 0.017) in dogs with recurrence (n = 3) than in dogs without recurrence for at least one year after hypophysectomy (n = 7). In dogs with csACTs, two miRNAs (miR-483-3p and miR-223-3p) were differentially expressed compared to healthy dogs. Additionally, miR-141-3p was expressed significantly lower (p = 0.009) in dogs with csACTs that had a histopathological Utrecht score of ≥ 11 compared to those with a score of < 11. These results indicate that circulating miRNAs have the potential to be noninvasive biomarkers in dogs with Cushing′s syndrome that may contribute to clinical decision-making.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating microRNAs as noninvasive biomarkers for canine Cushing’s syndrome

Sanders

Veldhuizen

Kooistra

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…In another recent study, we have compared the diagnostic applicability of urinary and whole plasma derived miR-483-5p [74]. Significant overexpression of whole plasma miR-483-5p was again confirmed in ACC relative to ACA, but although despite being detectable in the urine, no difference in urinary miR-483-5p was found between ACA and ACC.…”

Section: Circulating Mirna As Biomarkers In Accmentioning

confidence: 91%

“…There have been eight studies investigating the pattern of extracellular miRNAs in adrenocortical tumors (ACT) to date [24,51,[69][70][71][72][73][74] (Table 3).…”

Section: Circulating Mirna As Biomarkers In Accmentioning

confidence: 99%

Non-Coding RNAs in Adrenocortical Cancer: From Pathogenesis to Diagnosis

Decmann

Perge

Turai

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

Non-coding RNA molecules including microRNAs and long non-coding RNAs (lncRNA) have been implicated in the pathogenesis of several tumors and numerous data support their applicability in diagnosis as well. Despite recent advances, the pathogenesis of adrenocortical cancer still remains elusive and there are no reliable blood-borne markers of adrenocortical malignancy, either. Several findings show the potential applicability of microRNAs as biomarkers of malignancy and prognosis, and there are some data on lncRNA as well. In this review, we present a synopsis on the potential relevance of non-coding RNA molecules in adrenocortical pathogenesis and their applicability in diagnosis from tissue and blood.

show abstract

“…Furthermore, the number of CTCs was found to correlate with the presence of miR-483-5p, which was also present in serum of ACC patients [163]. The diagnostic potential of this and other micro-RNAs in serum has been studied by several research groups (Table 3) and has shown to be quite accurate for miR-34a, miR-483-5p, miR-195, miR-139-5p, miR-335, miR-376a and for combinations of miR-210/181b and miR-100/181b [127,130,135,164,165]. To date, the presence of mutations in cfDNA within serum samples of ACC patients was assessed in two studies.…”

Section: Liquid Biopsiesmentioning

confidence: 93%

How to Differentiate Benign from Malignant Adrenocortical Tumors?

Viëtor

Creemers

Kemenade

et al. 2021

Cancers

View full text Add to dashboard Cite

Adrenocortical carcinoma (ACC) is a rare cancer with a poor prognosis. Adrenal incidentalomas are, however, commonly identified in clinical practice. Discrimination between benign and malignant adrenal tumors is of great importance considering the large differences in clinical behavior requiring different strategies. Diagnosis of ACC starts with a thorough physical examination, biochemical evaluation, and imaging. Computed tomography is the first-level imaging modality in adrenal tumors, with tumor size and Hounsfield units being important features for determining malignancy. New developments include the use of urine metabolomics, also enabling discrimination of ACC from adenomas preoperatively. Postoperatively, the Weiss score is used for diagnosis of ACC, consisting of nine histopathological criteria. Due to known limitations as interobserver variability and lack of accuracy in borderline cases, much effort has been put into new tools to diagnose ACC. Novel developments vary from immunohistochemical markers and pathological scores, to markers at the level of DNA, methylome, chromosome, or microRNA. Molecular studies have provided insights into the most promising and most frequent alterations in ACC. The use of liquid biopsies for diagnosis of ACC is studied, although in a small number of patients, requiring further investigation. In this review, current diagnostic modalities and challenges in ACC will be addressed.

show abstract

Comparison of plasma and urinary microRNA-483-5p for the diagnosis of adrenocortical malignancy

Cited by 17 publications

References 29 publications

Circulating microRNAs as noninvasive biomarkers for canine Cushing’s syndrome

Circulating microRNAs as noninvasive biomarkers for canine Cushing’s syndrome

Non-Coding RNAs in Adrenocortical Cancer: From Pathogenesis to Diagnosis

How to Differentiate Benign from Malignant Adrenocortical Tumors?

Contact Info

Product

Resources

About